Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS Trypanosoma cruzi infection in HeLa cells

ABSTRACT: Single-probe single cell mass spectrometry (SCMS) analysis contains 3 sets of experiments: 1. SCMS analysis of 4 groups of cells: infected, bystanders, stained and control cells 2. SCMS analysis of 3 groups of cells (2 replicates): infected, correctly classified bystander, misclassified bystander cells. 3. SCMS-MS of 5 glycerophosphocholines at m/z 768.583, 780.5460, 782.5630, 808.5770 and 810.5940 that were acquired from individual HeLa cells.

INSTRUMENT(S): LTQ Orbitrap XL

ORGANISM(S): Homo Sapiens (ncbitaxon:9606) Trypanosoma Cruzi (ncbitaxon:5693)

SUBMITTER: Laura Isobel McCall Zhibo Yang

PROVIDER: MSV000089503 | GNPS | Fri May 20 07:54:00 BST 2022

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Shared Molecules

Only show the datasets with similarity scores above: 0.5

Threshold

0.5

Similar Datasets

Trypanosoma cruzi infection in HeLa cells

Project description:Single-probe single cell mass spectrometry (SCMS) analysis contains 3 sets of experiments: 1. SCMS analysis of 4 groups of cells: infected, bystanders, stained and control cells 2. SCMS analysis of 3 groups of cells (2 replicates): infected, correctly classified bystander, misclassified bystander cells. 3. SCMS-MS of 5 glycerophosphocholines at m/z 768.583, 780.5460, 782.5630, 808.5770 and 810.5940 that were acquired from individual HeLa cells.

2022-05-20 | MSV000089503 | MassIVE

Tolerance associated gene expression following allogeneic hematopoietic cell transplantation

Project description:Biologic markers of immune tolerance may facilitate tailoring of immune suppression duration after allogeneic hematopoietic cell transplantation (HCT). In a cross-sectional study, peripheral blood samples were obtained from tolerant (n=15, median 38.5 months post-HCT) and non-tolerant (n=17, median 39.5 post-HCT) HCT recipients and healthy control subjects (n=10) for analysis of immune cell subsets and differential gene expression. There were no significant differences in immune subsets across groups. We identified 281 probe sets unique to the tolerant (TOL) group and 122 for non-tolerant (non-TOL). These were enriched for process networks including NK cell cytotoxicity, antigen presentation, lymphocyte proliferation, and cell cycle and apoptosis. Differential gene expression was enriched for CD56, CD66, and CD14 human lineage-specific gene expression. Differential expression of 20 probe sets between groups was sufficient to develop a classifier with > 90% accuracy, correctly classifying 14/15 TOL cases and 15/17 non-TOL cases. These data suggest that differential gene expression can be utilized to accurately classify tolerant patients following HCT. Prospective investigation of immune tolerance biologic markers is warranted.

2015-05-25 | GSE64300 | GEO

Global analysis of the molecular targets of MBNL1 and CELF1 proteins and their potential role in DM1

Project description:Myotonic dystrophy type 1 (DM1) is caused by the nuclear accumulation of mutant DMPK mRNA containing CUG-repeat expansions, resulting in a trans-dominant effect on RNA processing by sequestration of MBNL1 and activation of CELF1 splicing regulators. Here, we present a comprehensive study of the MBNL1 and CELF1-regulated splicing in the HeLa cell line that may participate in the complex phenotype of the DM1 disease. We have performed human GeneChip Exon array experiments with RNAs extracted from HeLa cells in which MBNL1 or CELF1 were silenced or over-expressed. MBNL1 or CELF1-silenced HeLa cells showed changes in the expression of 170 probe sets (150 genes) and 893 probe sets (613 genes), whereas MBNL1 or CELF1 over-expression on these cells had 812 probe sets (589 genes) and 684 probe sets (531 genes) altered, respectively. In MBNL1-silenced cells we have found and validated by RT-qPCR the exclusion of RASIP1 exon 4 and of KIF13A exon 26 and the inclusion of MBNL2 exon 5. Furthermore, we have found exclusion of LCOR exon 6 and PIP4K2C exon 1, and inclusion TCF12 exon 16, with dependence on the silencing degree of MBNL1, In MBNL1 over-expressed HeLa cells we have found and validated by RT-qPCR a potent inclusion of CD44 exon 8, CD44 exon 11 and the 3´UTR of TRAF2. We have then mimicked the misregulation of MBNL1 and CELF1 protein levels of DM1 in HeLa cells, finding new altered splicing events. These alterations were found in genes that encode proteins involved in myoblast differentiation and migration (CD44, RASIP1) and muscle development (TCF12 transcription factor), estrogen and thyroid receptor interactor (LCOR), as well as proteins involved in transduction signaling pathways (PIP4K2C, TRAF2) and intracellular trafficking (KIF13A). These results provide potential contributing genes that could help to explain the complex phenotype of the DM1 disease.

2016-12-21 | GSE41987 | GEO

Genomic Strategies Identify the Antitumor Agent Apratoxin A as a Potent Antagonist of FGF Signaling and STAT3 Activation

Project description:Total RNA was extracted from apratoxin A or vehicle treated HT29 cells using the RNeasy Mini Kit (Qiagen). Probe values from CEL files were condensed to probe sets using Rosetta Resolver software. Resolver ANOVA analysis was then performed between groups. Keywords: time course and dose

2006-02-08 | GSE2742 | GEO

microRNA expression profiling in HPV-16/HIV associated Cervical Cancer

Project description:Identifying the differentially expressed miRNAs in Cervical cancer patients infected with only one virus i.e. either HIV or HPV-16 and patients infected with both viruses HIV and HPV-16 with respect to their controls which is the healthy population not infected by either HIV or any HPV The miRNA array was performed using the affymetrix GeneChip® miRNA 3.0 Array (Affymetrix, Santa Clara, California, United States). The chip was processed using a commercial Affymetrix array service (GeneTech Biotechnology Limited Company, Shanghai, China). The affymetrix GeneChip® miRNA 3.0 Array contains 2,999 probe sets unique to human, mouse and rat pre-miRNA hairpin sequences, 2,216 human snoRNA and scaRNA probe sets and covers 153 organisms (19,724 probe sets). Raw data sets were extracted from all Cel files (raw intensity file) after scanning of slides. These raw data sets were separately analyzed using Expression Console and GeneSpring GX12.5 software followed by differential miRNA expression, fold change & cluster analysis.

2018-08-01 | GSE81137 | GEO

Falcon Probe: A High-Pressure and Robust Sampling Interface for Coupling Lossless Liquid Chromatography Injection with In-Situ Nanoliter-Scale Sample Pretreatment

Project description:HeLa protein digest and single 293 cell proteome data analyzed by the Falcon probe-based LC-MS analysis system.

2024-05-24 | PXD052544 |

Untreated vs. Camptothecin Treated HeLa cells

Project description:Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. The response of tumor cells to the unusual form of DNA damage caused by topoisomerase poisons such as camptothecin (CPT) is poorly understood, and knowledge regarding which drugs can be effectively combined with CPT is lacking. To better understand the response of tumor cells to CPT and to identify potential targets for adjuvant therapy, we examined global changes in mRNA abundance in HeLa cells after CPT treatment using Affymetrix U133A GeneChips, which include all annotated human genes (22,283 probe sets). Statistical analysis of the data using a Bayesian/Cyber t test and a modified Benjamini and Hochberg correction for multiple hypotheses testing identified 188 probe sets that are induced and 495 that are repressed 8 h after CPT treatment at a False Discovery Rate of <0.05 and a minimum 3-fold change. This pharmacogenomic approach led us to identify two pathways that are CPT induced: (a) the epidermal growth factor receptor; and (b) nuclear factor-kappaB-regulated antiapoptotic factors. Experiments using HeLa cells in our lab and prior animal model studies performed elsewhere confirm that inhibitors of these respective pathways super-additively enhance CPT's cytotoxicity, suggesting their potential as targets for adjuvant therapy with CPT. Cancer Res. 2004 Mar 15;64(6):2096-104 Keywords = HeLa Keywords = Camptothecin Keywords: ordered

2004-05-18 | GSE1417 | GEO

Gene expression data of mRNA from hypothalamus sample of pig breed German Landrace with different coping behavior haplotype

Project description:47,880 probe-sets were screened, in the first part of this study, they were analysed for differential expression between two groups differing in coping behavior associated haplotype

2020-01-01 | GSE109154 | GEO

Gene expression data of mRNA from adrenal gland sample of pig breed German Landrace with different coping behavior haplotype

2020-01-01 | GSE109153 | GEO

Gene expression data of mRNA from amygdala sample of pig breed German Landrace with different coping behavior haplotype

2020-01-01 | GSE125080 | GEO